Reason for request
Inclusion
Clinical Benefit
Clinical Added Value
| no clinical added value |
NEVANAC 1 mg/ ml, eye drops, suspension does not offer any improvement in actual benefit (IAB V) over standard management of postoperative macular oedema associated with cataract surgery in diabetic patients. |
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
77uAdmyWuUUcA1gc
